Timo Lehtonen Transitions to Advisory Role at Bioretec After Leadership Period

Timo Lehtonen's New Role at Bioretec

In an important transition for Bioretec Ltd, Timo Lehtonen, the current Chief Technology Officer (CTO), will be stepping down from his executive role. As of July 6, 2026, he will assume the position of External Executive Advisor focused on technology strategy. This change marks a significant shift in Lehtonen's career as he continues to support the company from a different vantage point while no longer being part of the management team.

In his new role, Lehtonen will engage as a non-executive advisor. He will lend his expertise in various key areas including materials science, technology development, and the company's clinical and regulatory strategies. Furthermore, he will facilitate crucial external engagements with regulators, investors, and partners, ensuring that Bioretec continues to benefit from his extensive technological insights during this leadership transition.

Lehtonen has expressed his ongoing commitment to Bioretec by indicating his intention to participate in a planned rights issue announced by the company earlier in March. This indicates a continued investment in the company's future, reinforcing the notion that he remains deeply connected to Bioretec's mission and vision.

It is worth mentioning that Bioretec has chosen not to fill the CTO role on a direct basis after Lehtonen’s departure. Instead, the company plans to create two dedicated positions to cater to its operational needs in product development and clinical affairs. This strategic decision aims to ensure ongoing progress in Bioretec’s endeavors without excessive overlapping in leadership roles.

Sarah van Hellenberg Hubar-Fisher, the CEO of Bioretec, praised Lehtonen’s contributions: "Timo has been, and will continue to be, a valuable part of the Bioretec team. His leadership has shepherded Bioretec from early materials science to breakthrough designation leadership, establishing a solid foundation of world-class materials science and technology development." She expressed enthusiasm about Timo’s continuing journey with Bioretec in this new capacity.

Reflecting on his time with Bioretec, Lehtonen stated, "This is a natural moment for me to transition to a new advisory role, while continuing to support Bioretec going forward. Together, we have built a strong foundation in absorbable metal implant technology and advanced a promising product pipeline supported by substantial clinical and regulatory progress." His sentiment encapsulates a shared pride in the progress made by the Bioretec team and demonstrates his unwavering belief in the potential of the technologies they have developed.

Bioretec has been recognized as a pioneer in the medical device industry, particularly focused on transforming orthopedic care with fully biodegradable implant technologies. Their innovation, including the RemeOs™ product line, utilizes a high-performance magnesium alloy for improved surgical outcomes. This paradigm shift in orthopedic treatment through absorbable technologies represents a bright future for patient care, emphasizing more effective and user-friendly solutions.

The RemeOs implants are notably designed to be absorbed and replaced by natural bone, thus negating the necessity for secondary surgical procedures to remove the implants. The successful acquisition of market authorization in both the U.S. and Europe further amplifies the impact of Bioretec’s ongoing innovations.

Bioretec's journey illustrates the effective integration of science and healthcare, positioning itself as a leading force in advancing orthopedic treatments. With Timo Lehtonen continuing to support the company’s strategies in the advisory capacity, Bioretec is set to build upon its achievements and continue making significant strides in medical technology and patient care enhancement.

For additional information regarding Bioretec and their innovative products, you can visit their official website at www.bioretec.com.